Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Short Interest Down 14.0% in January
by Doug Wharley · The Cerbat GemLixte Biotechnology Holdings, Inc. (NASDAQ:LIXT – Get Free Report) was the recipient of a significant drop in short interest during the month of January. As of January 15th, there was short interest totaling 108,462 shares, a drop of 14.0% from the December 31st total of 126,115 shares. Approximately 1.6% of the company’s shares are sold short. Based on an average trading volume of 83,283 shares, the short-interest ratio is currently 1.3 days. Based on an average trading volume of 83,283 shares, the short-interest ratio is currently 1.3 days. Approximately 1.6% of the company’s shares are sold short.
Analyst Ratings Changes
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Lixte Biotechnology in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.
Read Our Latest Analysis on Lixte Biotechnology
Lixte Biotechnology Stock Down 5.1%
Lixte Biotechnology stock traded down $0.18 during trading hours on Tuesday, reaching $3.38. 40,821 shares of the company’s stock were exchanged, compared to its average volume of 104,674. The firm’s 50 day simple moving average is $3.85 and its 200 day simple moving average is $4.26. Lixte Biotechnology has a twelve month low of $0.64 and a twelve month high of $6.26. The firm has a market capitalization of $25.27 million, a PE ratio of -2.86 and a beta of 0.94.
Lixte Biotechnology (NASDAQ:LIXT – Get Free Report) last released its earnings results on Wednesday, November 12th. The company reported ($0.33) EPS for the quarter.
Lixte Biotechnology Company Profile
Lixte Biotechnology Holdings, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for the treatment of cancer. The company’s research centers on selectively targeting key enzymes and pathways involved in DNA damage response and cell cycle regulation, with the goal of creating novel oncology drugs that improve patient outcomes with manageable safety profiles.
Lixte’s lead programs include selective inhibitors of cell cycle checkpoints and related targets, designed to potentiate the effects of standard-of-care chemotherapies and overcome resistance mechanisms.